Capital Group Private Client Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-1,017
Closed -$785K – 279
2025
Q4
$785K Sell
1,017
-1,890
-65% -$1.28M 0.01% 216
2025
Q3
$1.63M Sell
2,907
-19,965
-87% -$11.3M 0.03% 185
2025
Q2
$12M Sell
22,872
-88,130
-79% -$49.2M 0.1% 133
2025
Q1
$70.4M Buy
111,002
+19,672
+22% +$13.5M 0.69% 37
2024
Q4
$65.1M Sell
91,330
-19,565
-18% -$16.4M 0.6% 44
2024
Q3
$117M Buy
110,895
+10,667
+11% +$11.9M 1.11% 23
2024
Q2
$105M Sell
100,228
-3,641
-4% -$3.53M 1.05% 22
2024
Q1
$100M Buy
103,869
+10,857
+12% +$10.3M 1.02% 24
2023
Q4
$81.7M Buy
93,012
+336
+0.4% +$277K 0.84% 32
2023
Q3
$76.3M Buy
92,676
+26,108
+39% +$20.5M 0.93% 31
2023
Q2
$47.8M Buy
66,568
+41,630
+167% +$32.1M 0.56% 63
2023
Q1
$20.5M Buy
24,938
+2,048
+9% +$1.54M 0.25% 101
2022
Q4
$16.5M Buy
22,890
+60
+0.3% +$44.3K 0.21% 114
2022
Q3
$15.7M Buy
22,830
+82
+0.4% +$51.6K 0.22% 111
2022
Q2
$13.4M Sell
22,748
-44
-0.2% -$28.6K 0.17% 120
2022
Q1
$15.9M Buy
+22,792
New +$14.4M 0.17% 120

Other funds holding REGN

Capital Group Private Client Services's REGN Position: Q1 2026 in Review

Capital Group Private Client Services sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 1,017 shares — an estimated $785K sold.

Capital Group Private Client Services first reported a position in REGN in Q1 2022 and held it in 16 quarters. The position peaked at $117M in Q3 2024. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Capital Group Private Client Services reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Capital Group Private Client Services sold 1,017 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $785K.
  • Capital Group Private Client Services first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 16 quarters.
  • Capital Group Private Client Services's Regeneron Pharmaceuticals position peaked at $117M in Q3 2024.
  • 1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Capital Group Private Client Services's 13F filing for Q1 2026, filed 13 May 2026.